Peripheral Nervous System Diseases: Clinical Trials

336 trials for Peripheral Nervous System Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

187 completed, 50 recruiting, 29 terminated, 21 unknown. 336 Phase 1, 123 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1336Completed 187, Recruiting 50, Terminated 29, Unknown 21, Active not recruiting 19, Withdrawn 13, Not yet recruiting 11, Enrolling by invitation 4, Suspended 2
Phase 2123Completed 56, Recruiting 24, Terminated 12, Active not recruiting 9, Withdrawn 8, Unknown 7, Not yet recruiting 4, Suspended 2, Enrolling by invitation 1

Follow Peripheral Nervous System Diseases: new trials by email Literature Review of Peripheral Nervous System Diseases trials Research Report on Peripheral Nervous System Diseases

Trials (filtered) newest first · largest first

All 336 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
scAAV1.tMCK.NTF3 - Charcot-Marie-Tooth Neuropathy Type 1A
Phase 1 / Phase 2WithdrawnNationwide Children's Hospital2027-04-012026-07-29
Simultaneous Engagement of Networks for Alleviating Pain (SENAP)
PFM-guided cortical stimulation - Neuropathic Pain, Postherpetic Neuralgia
Phase 1Not yet recruitingUniversity of Minnesota202027-01-012026-11-03
Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy
GEB-101 Injection - Hereditary Corneal Dystrophy, Corneal Abnormality
Phase 1 / Phase 2Not yet recruitingGenEditBio Limited302026-10-012026-09-10
Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain
Green Tea Leaf Extract Decaffeinated, Placebo Control - Neuropathic Pain, Cancer Treatment
Phase 1Not yet recruitingUniversity of Alabama at Birmingham202026-09-302026-08-21
OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis
glibenclamide, Placebo - Multiple Sclerosis, Neuropathic Pain
Phase 1Not yet recruitingUniversity of Maryland, Baltimore102026-09-012025-10-28
Psilocybin to Treat Depression in Spinal Cord Injury
Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder
Phase 1 / Phase 2RecruitingJames J. Peters Veterans Affairs Medical Center302026-08-062026-08-10
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST
Phase 1 / Phase 2RecruitingAnkit Mangla, MD172026-08-012026-08-11
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor
Phase 1 / Phase 2RecruitingArvinas Inc.4992026-07-292026-10-13
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Obinutuzumab β - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β
Phase 1 / Phase 2Not yet recruitingZhongming Qiu242026-07-152026-07-10
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
Y-4 tablet, Pregabalin capsule, Riluzole tablet - Healthy Male and Female Subjects
Phase 1Not yet recruitingNeurodawn Pharmaceutical Co., Ltd.112026-06-302026-06-01
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
[89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor
Phase 1RecruitingRobert Flavell, MD, PhD402026-06-152026-10-01
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 1RecruitingGirish Dhall, MD302026-06-092026-10-02
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
GB-4362, enfortumab vedotin (EV), Pembrolizumab - Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Phase 1RecruitingGenerate Biomedicines372026-06-082026-10-13
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1)
Phase 1 / Phase 2RecruitingAeRang Kim452026-06-012026-07-27
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
EC5026 oral tablet, Placebo oral tablet - Spinal Cord Injuries, Neuropathic Pain
Phase 1RecruitingEicOsis Human Health Inc.362026-05-012026-07-10
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Serabelisib, Sapanisertib, Fulvestrant - HR+ HER2- Breast Cancer
Phase 1 / Phase 2RecruitingFaeth Therapeutics322026-04-222026-07-02
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis
Phase 1RecruitingKite, A Gilead Company572026-04-102026-10-19
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
HPB-092 tablet - Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Phase 1RecruitingHangzhou Polymed Biopharmaceuticals, Inc.602026-04-102026-07-23
Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution - Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Phase 1 / Phase 2RecruitingFlorida A&M University202026-04-022026-04-29
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 1RecruitingTongji Hospital62026-04-012026-05-12

Showing 20 of 336. Sign in to see all of them.

Narrower conditions

Neuralgia (70)  ·  Hereditary Sensory and Autonomic Neuropathies (55)  ·  Neurofibrosarcoma (35)  ·  Neurofibromatosis 1 (30)  ·  Diabetic Neuropathies (26)  ·  Sarcoma (24)  ·  Pain (19)  ·  Sarcoma, Synovial (16)  ·  Breast Neoplasms (15)  ·  Chronic Pain (14)  ·  Neuralgia, Postherpetic (14)  ·  Rhabdomyosarcoma (13)  ·  Carpal Tunnel Syndrome (12)  ·  Leiomyosarcoma (12)

Broader conditions

Nervous System Diseases (334)  ·  Neuromuscular Diseases (334)  ·  Pathological Conditions, Signs and Symptoms (134)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (123)  ·  Genetic Diseases, Inborn (120)  ·  Neurodegenerative Diseases (116)  ·  Heredodegenerative Disorders, Nervous System (110)  ·  Neoplasms (109)  ·  Signs and Symptoms (108)  ·  Neurologic Manifestations (107)  ·  Neoplasms by Histologic Type (96)  ·  Polyneuropathies (85)  ·  Pain (81)  ·  Neoplasms, Nerve Tissue (77)

Interventions

AZD 6244 (9)  ·  Lidocaine (7)  ·  pembrolizumab (7)  ·  Everolimus (5)  ·  Fulvestrant (5)  ·  Cetuximab (4)  ·  Deoxycholic Acid (4)  ·  Pregabalin (4)  ·  Sodium Chloride (4)  ·  fludarabine (4)  ·  vixotrigine (4)  ·  6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo(d)thiazol-2(3H)-one (3)  ·  Cyclophosphamide (3)  ·  Doxorubicin (3)  ·  Immunoglobulins, Intravenous (3)

Sponsors

National Cancer Institute (NCI) (14)  ·  AstraZeneca (9)  ·  Biogen (8)  ·  Massachusetts General Hospital (6)  ·  Washington University School of Medicine (5)  ·  Center for Medicinal Cannabis Research (4)  ·  Novartis Pharmaceuticals (4)  ·  Novartis Vaccines (4)  ·  Stanford University (4)  ·  Cascadian Therapeutics Inc. (3)  ·  Children's Hospital Medical Center, Cincinnati (3)  ·  GL Pharm Tech Corporation (3)  ·  Johns Hopkins University (3)  ·  University Children's Hospital, Zurich (3)  ·  University of Alberta (3)

Countries

United States (186)  ·  Canada (25)  ·  United Kingdom (25)  ·  China (22)  ·  Spain (19)  ·  Australia (17)  ·  South Korea (16)  ·  France (15)  ·  Switzerland (14)  ·  Netherlands (10)  ·  Germany (9)  ·  Japan (9)  ·  Egypt (8)  ·  Belgium (7)  ·  Denmark (7)

Top investigators

Brigitte C Widemann, M.D. (4)  ·  Richard R Anderson, MD (3)  ·  Simon Haroutounian, PhD (3)  ·  AeRang Kim, MD, PhD (2)  ·  Albert Lo, MD PhD (2)  ·  Jason R Fangusaro (2)  ·  Min-Gul Kim, Ph.D. (2)

Results publications

PMID 35295458, PMID 38507752, PMID 11145807, PMID 11705489, PMID 12384756, PMID 12473512, PMID 12528778, PMID 12897484, PMID 12957454, PMID 15010069, PMID 15115710, PMID 15454701, PMID 15592836, PMID 16192528, PMID 16371894, PMID 16466122, PMID 17296917, PMID 18362604, PMID 19027342, PMID 19088049, PMID 19356391, PMID 19387178, PMID 19717722, PMID 19800329, PMID 19801812, PMID 20798179, PMID 21047224, PMID 21185118, PMID 21764354, PMID 21764821, PMID 22048718, PMID 22262746, PMID 22934754, PMID 23131255, PMID 23325902, PMID 23382028, PMID 23798472, PMID 24088271, PMID 24327173, PMID 25218827, PMID 25858498, PMID 25885543, PMID 25962165, PMID 26032776, PMID 26381530, PMID 26928074, PMID 28029918, PMID 28158151, PMID 29023494, PMID 29066505

NIH funding

2017 (4), 2023 (3), 2014 (2), 2015 (2), 2018 (2), UM1CA081457 (2), 2005 (1), 2016 (1), 2019 (1), 2025 (1), K08CA245181 (1), N01CM00071 (1), N01CM62206 (1), P30CA008748 (1), P30CA014599 (1)